

**AHNCI Neurologic Oncology Program Tumor Board**

Friday, January 31, 2020

12:00-1:00 p.m.

Jho Conference Room, 6th Floor, AGH

Join Zoom Meeting

<https://zoom.us/j/519670691>

Meeting ID: 519 670 691

Dial by your location

+1 646 558 8656

Dr. Linda Xu with be presenting a summary of yesterday’s presentation by Dr. Sloan during the first 15 minutes of tumor conference.

**Cases to be discussed**

|  |  |  |  |
| --- | --- | --- | --- |
| **Case** | **De-identified patient** | **Reason** | **Presenter** |
| 1 | MM MRN: 10177301 | Metastatic SCLC (brain met on 12/14/18 s/p resection followed by  WBRT completed on 1/30/2019). Repeat MRI brain on 1/24/2020 shows new enhancing lesion within the left periventricular deep white matter.   Radiology review | JB |
| 2 | MR MRN: 3708245 | Metastatic lung cancer; review MRI non contrast with concern for leptomenigeal disease/pineal gland involvement | RS |
| 3 | RS MRN:  11825975 | 42 y/o male with newly diagnosed GBM s/p resection by Dr. Yu on 1/23/2020. Presenting to review plan for chemo/radiation. | TR |
| 4 | SD MRN:  10547708 | 70 y.o. female who was referred to the Neuro-Oncology clinic for her neurological symptoms that have not been diagnosed, but wanted evaluated to r/o lymphoma. Patient has history of breast cancer, and underwent chemo and radiation. Paraneoplastic panel negative. Presenting to review MRI Brain 1/29/20. | TR |
| 5 | TR MRN:  4480633 | 52 y/o male with Left frontal Glioblastoma, IDH Wild Type, MGMT methylated (8.54),  diagnosed 6/14/2017. Post treatment change noted on MRI Brain 1/30/2020. Presenting to review imaging. | TR |
| 6 | DN MRN:  10126006 | 60 y/o male with Right frontal Glioblastoma, WHO Grade IV, MGMT methylated (64.24), IDH wild-type, diagnosed 10/12/2018. Increased enhancement noted on MRI Brain 1/29/2020. Presenting to review imaging. | TR |
| 7 | JE MRN:  4191784 | 46 y/o male with Left Parietal Glioblastoma, WHO Grade IV, MGMT sample insufficient, IDH Wild-type, diagnosed 8/13/2019. Currently admitted to AGH with acute psychosis. Possibly steroid psychosis. Imaging is stable. Presenting to review MRI. | TR |
| 8 | JW MRN: 4879692 | WHO grade III anaplastic astrocytoma | RF |
| 9 |  |  |  |
| 10 |  |  |  |
| 11 |  |  |  |
| 12 |  |  |  |

AHN CME Credit

**TEXT 412-301-9919**save this number to your contacts–  
will use this **same** number every week to text your attendance

**Today’s SMS Code: WAKWON**

You must text within THREE hours of the tumor board. You will receive a text confirming receipt and then an email to complete the evaluation. Once the evaluation is completed credit is registered.

Objectives

Upon completion of this activity, participants will have a better understanding of decision-making for complex neurologic oncology problems and be armed with clinical pathways to improve care.

Accreditation:

Allegheny General Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing education for physicians. Allegheny General Hospital designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure:

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) and the policy of Allegheny General Hospital, presenters must disclose all relevant financial relationships, which in the context of their presentation(s), could be perceived as a real or apparent conflict of interest, (e.g., ownership of stock, honoraria or consulting fees). Any identifiable conflicts will be resolved prior to the activity. Any such relationships will be disclosed to the learner prior to the presentation(s).

Moderators: Tulika Ranjan, MD and Stephen Karlovits, MD